Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Gounder, MM; Somaiah, N; Attia, S; Chawla, SP; Villalobos, VM; Chmielowski, B; Burgess, MA; Schwartz, GK; Riedel, RF; von Mehren, M; Wagner, AJ; Choy, E; Verma, S; Mudenda, B; Sadanowicz, M; Shah, JJ; Li, L; Shacham, S; Kauffman, MG; Abdul Razak, AR

Published Date

  • May 20, 2018

Published In

Volume / Issue

  • 36 / 15_suppl

Start / End Page

  • 11512 - 11512

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2018.36.15_suppl.11512